Apellis Pharmaceuticals
APLS
APLS
316 hedge funds and large institutions have $9.71B invested in Apellis Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 69 funds opening new positions, 100 increasing their positions, 119 reducing their positions, and 30 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
13% more funds holding
Funds holding: 279 → 316 (+37)
4.91% less ownership
Funds ownership: 96.41% → 91.5% (-4.9%)
16% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 119
Holders
316
Holding in Top 10
15
Calls
$229M
Puts
$166M
Top Buyers
| 1 | +$226M | |
| 2 | +$191M | |
| 3 | +$48.4M | |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$43.6M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$42.7M |
Top Sellers
| 1 | -$265M | |
| 2 | -$174M | |
| 3 | -$147M | |
| 4 |
State Street
Boston,
Massachusetts
|
-$63.5M |
| 5 |
Jennison Associates
New York
|
-$58.5M |